- Home
- OPFI vs CADL Comparison
OPFI vs CADL Comparison
Compare OPFI & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPFI
- CADL
- Stock Information
- Founded
- OPFI 2009
- CADL 1999
- Country
- OPFI United States
- CADL United States
- Employees
- OPFI N/A
- CADL N/A
- Industry
- OPFI Finance: Consumer Services
- CADL Biotechnology: Pharmaceutical Preparations
- Sector
- OPFI Finance
- CADL Health Care
- Exchange
- OPFI Nasdaq
- CADL Nasdaq
- Market Cap
- OPFI 205.2M
- CADL 244.2M
- IPO Year
- OPFI N/A
- CADL 2021
- Fundamental
- Price
- OPFI $8.08
- CADL $4.78
- Analyst Decision
- OPFI Buy
- CADL Strong Buy
- Analyst Count
- OPFI 2
- CADL 4
- Target Price
- OPFI $7.50
- CADL $21.00
- AVG Volume (30 Days)
- OPFI 1.0M
- CADL 1.0M
- Earning Date
- OPFI 05-07-2025
- CADL 05-13-2025
- Dividend Yield
- OPFI 3.14%
- CADL N/A
- EPS Growth
- OPFI N/A
- CADL N/A
- EPS
- OPFI 0.36
- CADL N/A
- Revenue
- OPFI $276,770,000.00
- CADL N/A
- Revenue This Year
- OPFI $112.50
- CADL N/A
- Revenue Next Year
- OPFI $7.84
- CADL N/A
- P/E Ratio
- OPFI $22.13
- CADL N/A
- Revenue Growth
- OPFI 22.23
- CADL N/A
- 52 Week Low
- OPFI $2.56
- CADL $3.79
- 52 Week High
- OPFI $17.73
- CADL $14.60
- Technical
- Relative Strength Index (RSI)
- OPFI 39.26
- CADL 35.89
- Support Level
- OPFI $7.81
- CADL $4.41
- Resistance Level
- OPFI $8.49
- CADL $5.33
- Average True Range (ATR)
- OPFI 0.60
- CADL 0.45
- MACD
- OPFI 0.00
- CADL 0.03
- Stochastic Oscillator
- OPFI 23.28
- CADL 33.23
About OPFI OppFi Inc.
OppFi Inc is a tech-enabled, mission-driven specialty finance platform that broadens the reach of community banks to extend credit access to everyday Americans. It recognizes revenue through finance charges on installment and SalaryTap contracts based on the interest method.
About CADL Candel Therapeutics Inc.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.